Evidence map›Paper›PMID 33420682›Full record

Observational studyJournal of cardiovascular translational research2021

Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary Syndromes.

Roberto Martín-Asenjo, John Gregson, Xavier Rossello, Frans Van de Werf, Jesús Medina, Nicolas Danchin, Stuart Pocock, Héctor Bueno

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of cardiovascular translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01171404 (Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01171404 completednot on this map

Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients

TypeobservationalSponsorAstraZenecaRan2010 to 2013Enrolled10,568ConditionsACS, Acute Coronary Syndrome, Myocardial Infarction, Unstable Angina
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 4 countries.

Roberto Martín-AsenjoCardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
John GregsonDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
Xavier RosselloDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0001-6783-8463
Frans Van de WerfDepartment of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Jesús MedinaGlobal Medical Affairs, AstraZeneca, Madrid, Spain.
Nicolas DanchinHôpital Européen Georges Pompidou & René Descartes University, Paris, France.
Stuart PocockDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
Héctor BuenoCardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. hector.bueno@cnic.es.
Spanish National Centre for Cardiovascular Research · ESAstraZeneca (Spain) · ESHospital Universitario 12 De Octubre · ESKU Leuven · BELondon School of Hygiene & Tropical Medicine · GBUniversidad Complutense de Madrid · ESUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antithrombotic drug use for acute coronary syndromes (ACS) varies considerably. The number of antithrombotic drugs (excluding oral anticoagulants) used pre- and in-hospital was recorded in ACS survivors enrolled at hospital discharge in the long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndrome patients (EPICOR) registry ( NCT01171404 ), a prospective cohort study. Among 10,568 patients, the number of antithrombotic drugs used early/patient ranged from 0 to 8 (interquartile range = 3-4). Overall, 250 patients (2.4%) experienced ≥ 1 in-hospital ischemic event and 343 (3.2%) ≥ 1 non-fatal bleeding event. While there was no difference in the rate of ischemic events (p = 0.75 for-trend) according to the number of antithrombotic drugs, a significantly higher incidence of non-fatal bleeds was observed (p < 0.0001 for-trend), with OR = 1.68 (95%CI = 1.51-1.88) per additional antithrombotic drug, which remained after adjustment by patient characteristics. In conclusion, careful balancing of the short-term risks for ischemic and bleeding events should be considered when adding new antithrombotic drugs.

Indexed as

Acute Coronary SyndromeAgedCardiology Service, HospitalDrug Utilization ReviewEmergency Medical ServicesEuropeFemaleFibrinolytic AgentsHemorrhageHumansIncidenceIschemiaLatin AmericaMaleMiddle AgedPractice Patterns, Physicians'Fibrinolytic AgentsAcute coronary syndromeAntithrombotic drugsBleedingCardiac risk factors and preventionQuality and outcomes of care

Identifiers

PMID33420682
OpenAlexW3119571249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.